Amylin Pharmaceuticals Income Statement
View: Annual | Quarterly
| Dec 08 | Dec 07 | Dec 06 | |
|---|---|---|---|
| Revenue | 840.1 | 781.0 | 510.9 |
| Cost of Goods Sold | 91.6 | 65.5 | 50.1 |
| Gross Profit | 748.5 | 715.5 | 460.8 |
| Gross Profit Margin | 89.1% | 91.6% | 90.2% |
| SG&A Expense | 395.1 | 391.0 | 282.0 |
| Depreciation & Amortization | 33.3 | 21.6 | 16.2 |
| Operating Income | -- | -- | -- |
| Operating Margin | -- | -- | -- |
| Nonoperating Income | (14.9) | (290.9) | -- |
| Nonoperating Expenses | (3.2) | -- | -- |
| Income Before Taxes | -- | -- | -- |
| Income Taxes | -- | -- | -- |
| Net Income After Taxes | 0.0 | 0.0 | 0.0 |
| Continuing Operations | (315.4) | (211.1) | (218.9) |
| Discontinued Operations | -- | -- | -- |
| Total Operations | (315.4) | (211.1) | (218.9) |
| Total Net Income | (315.4) | (211.1) | (218.9) |
| Net Profit Margin | -- | -- | -- |
| Diluted EPS from Total Net Income ($) | (2.30) | (1.59) | (1.78) |
| Dividends per Share | 0.00 | 0.00 | 0.00 |
© 2009 Morningstar, Inc. Financial Data provided by
